LQZ-7I is a novel selectively inhibitor of survivin dimerization with IC50s of 4.8 µM and 3.1 µM in prostate cancer cell lines PC-3 and C4-2, respectively. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors.
Molecular Weight | 348.35 |
Formula | C₂₀H₁₄F₂N₄ |
CAS Number | 195822-23-2 |
Solubility (25°C) | DMSO 70 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Survivin Products |
---|
GDP366
GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. |
YM155
YM155 (Sepantronium Bromide) is a novel small molecule that suppresses transactivation of survivin through direct binding to its promoter. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.